Antibody binding specifically to TDP-43 aggregate
The present invention provides an antibody that specifically binds to an abnormal TDP-43 protein aggregate, an agent comprising the antibody for detecting a TDP-43 proteinopathy lesion, and a method for detecting or diagnosing a TDP-43 proteinopathy lesion by using the antibody.
1. A purified antibody that binds specifically to the following protein (a) or (b):
(a) a protein consisting of an amino acid sequence in which at least one amino acid residue selected from the group consisting of amino acid residues 393, 403, 404, 409 and 410 of the amino acid sequence represented by SEQ ID NO:1 is phosphorylated; or
(b) a phosphorylated partial peptide selected from the group consisting of amino acid sequences set forth in SEQ ID No: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11,
wherein said antibody does not bind with an unphosphorylated amino acid sequence represented by SEQ ID NO:1 and with an unphosphorylated partial peptide selected from the group consisting of amino acid sequences set for the in SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.
2. The purified antibody according to claim 1 , which can bind to a site of the protein (a) or the partial peptide (b) that has been structurally altered by phosphorylation.
3. The purified antibody according to claim 1 , wherein the phosphorylation is induced by casein kinase 1.
4. The purified antibody according to claim 1 , wherein the antibody is a monoclonal antibody.
5. The purified antibody according to claim 1 , wherein the antibody is a polyclonal antibody.
6. A hybridoma that produces the antibody according to claim 4 .
7. An agent for detecting phosphorylated TDP-43, comprising the purified antibody according to claim 1 .
8. An agent for detecting a TDP-43 proteinopathy lesion, comprising the purified antibody according to claim 1 .
9. An agent for diagnosing a TDP-43 proteinopathy, comprising the purified antibody according to claim 1 .
10. A pharmaceutical composition comprising:
the purified antibody according to claim 1 as an active element; and
a pharmaceutically acceptable carrier.
11. The antibody according to claim 1 , wherein said at least one amino acid residue is at least one selected from the group consisting of amino acid residues 409 and 410 of the amino acid sequence represented by SEQ ID NO:1.